(A) Actuarial survival, (B) leukemia-free survival (LFS), and (C) relapse risk of 55 patients transplanted in first CR for MDS, sAML, or therapy-related MDS/leukemia compared with 110 matched patients transplanted in first CR for de novo AML. MDS refers to myelodysplastic syndromes, secondary AML, and therapy related MDS/AML; AML refers to de novo AML.